Abstract:Prostate cancer (PCa) is one of the most common malignancies in the urinary system, and early diagnosis and treatment can significantly improve patient prognosis. Metabolomics is an essential branch of systems biology, among which urine metabolomics holds remarkable advantages in the identification and screening of biomarkers for prostate cancer. Numerous studies have reported the application of urine metabolomics in prostate cancer, identifying multiple relevant metabolic biomarkers in urine. In this review, we will provide a comprehensive overview of the application and related challenges of urine metabolomics in the early diagnosis, disease monitoring, prognostic evaluation, and personalized therapy in the field of prostate cancer.